U vindt
wetenschappelijke informatie over talrijke studies in de Database on Clinical Studies and Case Reports
·
Verbetering van de symptomen of positieve
evaluatie door de auteurs
o
Geen relevante verandering in de symptomen of
negatieve evaluatie door de auteurs
v Verslechtering
van de symptomen
Inhoudstafel
Misselijkheid en Braken – Kanker Chemotherapie
Misselijkheid en Braken – Radiotherapie
Misselijkheid en Braken – Metastase
Misselijkheid en Braken – Heelkunde
Misselijkheid en Braken – HIV/AIDS
Misselijkheid en Braken – Behandeling Hepatitis C
Misselijkheid en Braken – Zwangerschap
Misselijkheid en Braken – Reisziekte
Misselijkheid en Braken – Andere
Misselijkheid en Braken – Gezonde Studieobjecten
Eetlustverlies – Ziekte van Alzheimer
Eetlustverlies - Anorexia nervosa
Eetlustverlies – Gezonde Studieobjecten
Spasticiteit – Multiple Sclerose
Spasticiteit – Ruggenmergletsels
Spasticiteit – Diverse Oorzaken
Pijn – Chronisch, Neuropatisch/Multiple Sclerose
Pijn – Acuut, Gezonde Studieobjecten
Amyotrofe Laterale Sclerose (ALS)
Prikkelbare Darm Syndroom, Diarree
L-Dopa-geïnduceerde Dyskinesie (Tardieve Dyskinesie)
Hyperkinetische Bewegingsstoornis
Attention-Deficit/Hyperactivity Disorder (ADHD)
Obsessief-Compulsieve Stoornis
Intraoculaire Druk – Gezonde Studieobjecten
Visueel
vermogen in het donker
Bronchodilatatie – Gezonde Studieobjecten
COPD (Chronische Obstructieve Longziekte)
Posttraumatische Stressstoornis
·
Artim R, DiBella N. Tetrahydrocannabinol
(THC) plus prochlorperazine (PCZ) for refractory nausea and vomiting (N/V).
Proceedings of the American Society for Clinical Oncology 1983;2:84.
·
Chang AE, Shiling DJ, Stillman RC, Goldberg
NH, Seipp CA, Barofsky I. Delta-9-tetrahydrocannabinol as an antiemetics in
cancer patients receiving high-dose methotrexate. Annals of Internal Medicine
1979;91:819-824.
o
Chang AE, Shiling DJ, Stillman RC, Goldberg
NH, Seipp CA, Barofsky I, Rosenberg SA.. A prospective evaluation of
delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin
and cytoxan chemotherapy. Cancer 1981; 47: 1746-1751.
·
Colls BM, Ferry DG, Gray AJ, Harvey VJ,
McQueen EG. The antiemetic activity of tetrahydrocanabinol versus
metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy.
New Zealand Medical Journal 1980;91:449-451.
·
Ekert H, Waters KD, Jurk KH, Mobilia J,
Loughnan P. Ameriloration of cancer chemotherapy-induced nausea and vomiting by
delta-9-tetrahydrocannabinol. Medical Journal of Australia 1979;2:657-659.
·
Frytak S, Moertel CG, O'Fallon JR, Rubin J,
Creagan ET, O'Connnell MJ. Delta-9-tetrahydrocannabinol as an antiemetics for
patients receiving cancer chemotherapy. A comparison with prochlorperazine and
a placebo. Annals of Internal Medicine 1979;91:825-830.
·
Gralla RJ, Tyson LB, Bordin LA, Clark RA,
Kelsen DP, Kris MG. Antiemetic therapy: a review of recent studies and a report
of a random assignment trial comparing metoclopramide with
delta-9-tetrahydrocannabinol. Cancer Treatment Report 1984;68:163-172.
·
Kluin-Nelemans JC, Nelemans FA, Meuwissen
OJATh, Maes RAA. D9-tetrahydrocannabinol
(THC) as an antiemetic in patients treated with cancer chemotherapy; a
double-blind cross-over trial against placebo. Veterinary and Human Toxicology
1979;21:338-340.
·
Lane M, Vogel CL, Ferguson J, Krasnow S,
Saiers JL, Hamm J. Dronabinol and prochlorperazine in combination for treatment
of cancer chemotherapy-induced nausea and vomiting. Journal of Pain and Symptom
Management 1991;6:352-359.
·
Levitt M, Faiman C, Hawks R, Wilson A.
Randomized double blind comparison of delta-9-tetrahydroicannabinol (THC) and
marijuana as chemotherapy antiemetics. Proceedings of the American Society for
Clinical Oncology 1984;3:91.
·
Levitt M, Wilson A, Bowman D, Faiman C, Kemel
S, Krepart G. Dose vs response of tetrahydroannabinol (THC) vs prochlorperazine
as chemotherapy antiemetics. Proceedings of the American Society for Clinical
Oncology 1981;22:422.
·
McCabe M, Smith FP, Goldberg D, Macdonald J,
Woolley PV, Warren R. Efficacy of tetrahydrocannabinol in patients refractory
to standard anti-emetic therapy. Investigational New Drugs 1988;6:243-246.
·
Neidhart JA, Gagen MM, Wilson HE, Young DC.
Comparative trial of the antiemetic effects of THC and haloperidol.
International Journal of Clinical Pharmacology Research 1981; 21: 38-42S.
·
Orr LE, McKernan JF, Bloome B. Antiemetic
effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in
chemotherapy-associated nausea and emesis. Archives of Internal Medicine
1980;140:1431-433.
·
Sallan SE, Cronin C, Zelen M, Zinberg NE.
Antiemetics in patients receiving chemotherapy for cancer. A randomized
comparison of delta-9-tetrahydrocannabinol and prochlorperazine. New England
Journal of Medicine 1980;302:135-138.
·
Sallan SE, Zinberg NE, Frei E. Antiemetic
effect of delta-9-tetrahydrocannabinol in patients receiving cancer
chemotherapy. New England Journal of Medicine 1975;293:795-797.
·
Ungerleider JT, Andrysiak T, Fairbanks L,
Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy. A comparison
of oral delta-9-THC and prochlorperazine. Cancer 1982;50:636-645.
·
Ungerleider JT, Sarna G, Fairbanks LA,
Goodnight J, Andrysiak T, Jamison K. THC or compazine for the cancer
chemotherapy patient
the UCLA
study. Part II: patient drug preference. American Journal of Clinical Oncology
1985; 8: 142-147.
·
Meiri E, Jhangiani H, Vredenburgh JJ, Barbato
LM, Carter FJ, Yang HM, Baranowski V. Efficacy of dronabinol alone and in
combination with ondansetron versus ondansetron alone for delayed
chemotherapy-induced nausea and vomiting. Curr Med Res Opin 2007;23(3):533-43.
·
Levitt M, Faiman C, Hawks R, Wilson A. Randomized
double blind comparison of delta-9-tetrahydroicannabinol (THC) and marijuana as
chemotherapy antiemetics. Proceedings of the American Society for Clinical
Oncology 1984;3:91.
·
Duran M,
Pérez E, Abanades S, Vidal X, Saura C, Majem M, Arriola E, Rabanal M, Pastor A,
Farré M, Rams N, Laporte JR, Capellà D. Preliminary efficacy and safety of an
oromucosal standardized cannabis extract in chemotherapy-induced nausea and
vomiting. Br J Clin Pharmacol 2010;70(5):656-63.
·
Ahmedzai S, Carlyle DL, Clader IT, Moran F.
Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung
cancer chemotherapy. British Journal of Cancer 1983;48:657-663.
·
Chan HS, Correia JA, MacLeod SM. Nabilone
versus prochlorperazine for control of cancer chemotherapy-induced emesis in
children: a double-blind, crossover trial. Pediatrics 1987; 79: 946-952
·
Crawford SM, Buckman R. Nabilone and
metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a
double blind study. Medical Oncology and Tumor Pharmacotherapy 1986; 3: 39-42.
·
Cunningham D, Bradley CJ, Forrest GJ,
Hutcheon AW, Adams L, Sneddon M, et al. A randomized trial of oral nabilone and
prochlorperazine compared to intravenous metoclopramide and dexamethasone in
the treatment of nausea and vomiting induced by chemotherapy regimens
containing cisplatin or cisplatin analogues. European Journal of Cancer and
Clinical Oncology 1988; 24: 685-689.
·
Dalzell AM, Bartlett H, Lilleyman JS.
Nabilone: An alternative antiemetic for cancer chemotherapy. Archives of
Disease in Childhood 1986;61:502-505.
·
Einhorn LH, Nagy C, Furnas B, Williams SD.
Nabilone: an effective antiemetic in patients receiving cancer chemotherapy.
Journal of Clinical Pharmacology. 1981 Aug-Sep;21(8-9 Suppl):64S-69S.
·
George M, Pejovic MH, Thuaire M, Kramar A,
Wolff JP. Randomized comparative trial of a new anti-emetic: nabilone, in
cancer patients treated with cisplatin. Biomedicine and Pharmacotherapy 1983;
37: 24-27.
·
Herman TS, Einhorn LH, Jones SE, Nagy C,
Chester AB, Dean JC, et al. Superiority of nabilone over prochlorperazine as an
antiemetic in patients receiving cancer chemotherapy. New England Journal of
Medicine 1979; 300: 1295-1297.
·
Johansson R, Kilkku P, Groenroos M. A
double-blind, controlled trial of nabilone vs prochlorperazine for refractory
emesis induced by cancer chemotherapy. Cancer Treatment Reviews 1982; 9: 25-33.
·
Jones SE, Durant JR, Greco FA, Robertone A. A
multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced
nausea and vomiting. Cancer Treatment Reviews 1982; 9: 45-48
·
Levitt M. Nabilone vs placebo in the
treatment of chemotherapy-induced nausea and vomiting in cancer patients.
Cancer Treatment Reviews 1982; 9(suppl B): 49-53.
·
Nagy CM, Furnas BE, Einhorn LH, Bond WH.
Nabilone: antiemetic crossover study in cancer chemotherapy patients.
Proceedings of the American Society for Cancer Research 1978;19:30.
·
Niederle N, Schutte J, Schmidt CG. Crossover
comparison of the antiemetic efficacy of nabilone and alizapride in patients
with nonseminomatous testicular cancer receiving cisplatin therapy. Klinische
Wochenschrift 1986; 64: 362-365.
·
Niiranen Aila, Mattson K. A cross-over
comparison of nabilone and prochlorperazine for emesis induced by cancer
chemotherapy. American Journal of Clinical Oncology 1985;8:336-340.
·
Pomeroy M, Fennelly JJ, Towers M. Prospective
randomized double-blind trial of nabilone versus domperidone in the treatment
of cytotoxic-induced emesis. Cancer Chemotherapy and Pharmacology 1986;17:285-288.
·
Priestman SG, Priestman TJ, Canney PA. A
double-blind randomised cross-over comparison of nabilone and metoclopramide in
the control of radiation-induced nausea. Clinical Radiology 1987; 38: 543-544.
·
Steele N, Gralla RJ, Braun Jr DW, Young CW. Double-blind
comparison of the antiemetic effects of nabilone and prochlorperazine on
chemotherapy-induced emesis. Cancer Treatment Report 1980; 64: 219-224.
·
Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota
CH, Rieth TE. Double-blind, randomized, crossover trial of nabilone vs. placebo
in cancer chemotherapy. Cancer Treatment Reviews 1982; 9(Suppl B): 39-44
·
Citron ML, Herman TS, Vreeland F, Krasnow SH,
Fossieck BE, Jr. Antiemetic efficacy of levonantradol compared to
delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
Cancer Treatment Reports 1985;69:109-112.
·
Higi M, Niederle N, Bremer K, Schmitt G,
Schmidt CG, Seeber S. Levonantradol bei der Behandlung von
zytostatika-bedingter Nausea and Vomiting. Deutsche Medizinische Wochenschrift
1982; 107: 1232-1234.
·
Hutcheon AW, Palmer JB, Soukop M, Cunningham
D, McArdle C, Welsh J, et al. A randomised multicentre single blind comparison
of a cannabinoid anti-emetic (levonantradol) with ychlorpromazine in patients
receiving their first cytotoxic chemotherapy. European Journal for Cancer and
Clinical Oncology 1983; 19: 1087-1090
·
Stambaugh Jr JE, McAdams J, Vreeland F. Dose
ranging evaluation of the antiemetic efficacy and toxicity of intramuscular
levonantradol in cancer subjects with chemotherapy-induced emesis.
International Journal of Clinical Pharmacology Research1984; 24: 480-485
·
Abrahamov A, Abrahamov A, Mechoulam R. An
efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences
1995;56:2097-2102.
·
Vinciguerra V, Moore T, Brennan E. Inhalation
marijuana as an antiemetic for cancer chemotherapy. New York State Journal of
Medicine 1988;88:525-527.
·
Musty RE, Rossi R. Effects of smoked cannabis
and oral delta-9-tetrahydrocannabinol on nausea and emesis after cancer
chemotherapy: A review of state clinical trials. J Cannabis Ther 2001;1(1):29-42.
·
Doblin RE, Kleiman MA. Marijuana as
antiemetic medicine: a survey of oncologists' experiences and attitudes.
American Journal of Clinical Oncology 1991; 9: 1314-1319.
o
Schwartz RH, Voth EA, Sheridan MJ. Marijuana
to prevent nausea and vomiting in cancer patients: a survey of clinical
oncologists. South Medical Journal 1997;90(2):167-72.
·
Lucraft HH, Palmer MK. Randomised clinical trial
of levonantradol and chlorpromazine in the prevention of radiotherapy-induced
vomiting. Clinical Radiology 1982; 33: 621-622.
·
Zutt M, Hanssle H, Emmert S, Neumann C,
Kretschmer L. [Dronabinol for supportive therapy in patients with malignant
melanoma and liver metastases] [Article in German]. Hautarzt 2006;57(5):423-7.
·
Gonzalez-Rosales F, Walsh D. Intractable
nausea and vomiting due to gastrointestinal mucosal metastases relieved by
tetrahydrocannabinol (dronabinol). Journal of Pain and Symptom Management
1997;14(5):311-314.
·
Layeeque R, Siegel E, Kass R, Henry-Tillman RS,
Colvert M, Mancino A, Klimberg VS. Prevention of nausea and vomiting following
breast surgery. Am J Surg 2006;191(6):767-72.
·
Lewis IH, Campbell DN, Barrowcliffe MP.
Effect of nabilone on nausea and vomiting after total abdominal hysterectomy. British
Journal of Anaesthesia 1994; 73: 244-246.
·
de Jong BC, Prentiss D, McFarland W,
Machekano R, Israelski DM. Marijuana use and its association with adherence to
antiretroviral therapy among
HIV-infected persons with moderate to severe nausea. J Acquir Immune
Defic Syndr 2005;38(1):43-6.
·
Woolridge E, Barton S, Samuel J, Osorio J,
Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical
symptoms. J Pain Symptom Manage 2005;29(4):358-67.
·
Sidney S. Marijuana use in HIV-positive and
AIDS patients: Results of a an anonymous mail survey. J Cannabis Ther
2001;1(3-4):35-43.
·
Corless IB,
Lindgren T, Holzemer W, Robinson L, Moezzi S, Kirksey K, Coleman C, Tsai YF,
Sanzero Eller L, Hamilton MJ, Sefcik EF, Canaval GE, Rivero Mendez M,
Kemppainen JK, Bunch EH, Nicholas PK, Nokes KM, Dole P, Reynolds N. Marijuana
Effectiveness as an HIV Self-Care Strategy. Clin Nurs Res 2009;18(2):172-93.
·
Costiniuk CT, Mills E, Cooper CL. Evaluation
of oral cannabinoid-containing medications for the management of interferon and
ribavirin-induced anorexia, nausea and weight loss in patients treated for
chronic hepatitis C virus. Can J Gastroenterol 2008;22(4):376-80.
·
Sylvestre DL, Clements BJ, Malibu Y. Cannabis
use improves retention and virological outcomes in patients treated for
hepatitis C. Eur J Gastroenterol Hepatol 2006;18(10):1057-63.
·
Curry W-NL. Hyperemesis gravidarum and
clinical cannabis: To eat or not to eat? J Cannabis Ther 2002;2(3-4):63-83.
·
Westfall RE, Janssen PA, Lucas P, Capler R.
Survey of medicinal cannabis use among childbearing women: patterns of its use
in pregnancy and retroactive self-assessment of its efficacy against 'morning
sickness'. Complement Ther Clin Pract 2006;12(1):27-33.
·
Choukèr A, Kaufmann I, Kreth S, Hauer D,
Feuerecker M, Thieme D, Vogeser M, Thiel M, Schelling G. Motion sickness, stress and the
endocannabinoid system. PLoS One
2010;5(5):e10752.
·
Merriman AR,
Oliak DA. Use of medical
marijuana for treatment of severe intractable nausea after laparoscopic
Roux-en-Y gastric bypass surgery: case report. Surg Obes Relat Dis 2008;4(4):550-1.
·
Soderpalm AH, Schuster A, de Wit H.
Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on
nausea induced by syrup of ipecac. Pharmacology, Biochemistry and Behavior 2001;69(3-4):343-50.
·
Beal JE, Olson R, Laubenstein L, Morales JP,
Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV. Dronabinol as a
treatment for anorexia associated with weight loss in patients with AIDS.
Journal of Pain and Symptom Management 1995;10(2):89-97.
·
Timpone JG, Wright DJ, Li N, Egorin MJ, Enama
ME, Mayers J, Galetto G, and the DATRI 004 Study Group. The safety and
pharmacokinetics of single-agent and combination therapy with megestrol acetate
and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and
Human Retroviruses 1997;13:305-315.
·
Abrams DI, Hilton JF, Leiser RJ, Shade SB,
Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG,
Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term
effects of cannabinoids in patients with HIV-1 infection: a randomized,
placebo-controlled clinical trial. Ann Intern Med 2003;139(4):258-66.
·
Haney M, Rabkin J, Gunderson E, Foltin RW.
Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric
intake and mood. Psychopharmacology (Berl) 2005;181(1):170-8.
·
Haney M, Gunderson EW, Rabkin J, Hart CL,
Vosburg SK, Comer SD, Foltin RW. Dronabinol and marijuana in HIV-positive
marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr
2007;45(5):545-54.
·
Bedi G, Foltin RW, Gunderson EW, Rabkin J,
Hart CL, Comer SD, Vosburg SK, Haney M. Efficacy and tolerability of high-dose
dronabinol maintenance in HIV-positive marijuana smokers: a controlled
laboratory study. Psychopharmacology (Berl) 2010;212(4):675-86.
·
Haney M, Rabkin J, Gunderson E, Foltin RW.
Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric
intake and mood. Psychopharmacology (Berl) 2005;181(1):170-8.
·
Haney M, Gunderson EW, Rabkin J, Hart CL,
Vosburg SK, Comer SD, Foltin RW. Dronabinol and marijuana in HIV-positive
marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr
2007;45(5):545-54.
·
Gorter R, Seefried M, Volberding P.
Dronabinol effects on weight in patients with HIV infection. AIDS 1992;6:127.
·
Plasse TF, Gorter RW, Krasnow SH, Lane M,
Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol.
Pharmacology, Biochemistry and Behavior 1991;40:695-700.
·
Plasse T, Conant M, Gorter R, Shepard KV.
Dronabinol stimulates appetite and causes weight gain in HIV patients.
International Conference on AIDS 1992;8(3):122 (abstract no. PuB 7442).
·
Struwe M, Kaempfer SH, Geiger CJ, Pavia AT,
Plasse TF, Shepard KV, Ries K, Evans TG. Effect of dronabinol on nutritional
status in HIV infection. Annals of Pharmacotherapy 1993;27:827-831.
·
Beal JE, Olson R, Lefkowitz L, Laubenstein L,
Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW,
Shepard KV. Long-term efficacy and safety of dronabinol for acquired
immunodeficiency syndrome-associated anorexia. Journal of Pain and Symptom
Management 1997;14(1):7-14.
·
Dejesus E, Rodwick BM, Bowers D, Cohen CJ,
Pearce D. Use of dronabinol improves appetite and reverses weight loss in
HIV/AIDS-infected patients. J Int Assoc Physicians AIDS Care 2007;6(2):95-100.
·
Prentiss D, Power R, Balmas G, Tzuang G,
Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed
in a public health care setting. J Acquir Immune Defic Syndr 2004;35(1):38-45.
·
Woolridge E, Barton S, Samuel J, Osorio J,
Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical
symptoms. J Pain Symptom Manage 2005;29(4):358-67.
·
Sidney S. Marijuana use in HIV-positive and
AIDS patients: Results of a an anonymous mail survey. J Cannabis Ther
2001;1(3-4):35-43.
·
Corless IB,
Lindgren T, Holzemer W, Robinson L, Moezzi S, Kirksey K, Coleman C, Tsai YF,
Sanzero Eller L, Hamilton MJ, Sefcik EF, Canaval GE, Rivero Mendez M,
Kemppainen JK, Bunch EH, Nicholas PK, Nokes KM, Dole P, Reynolds N. Marijuana
Effectiveness as an HIV Self-Care Strategy. Clin Nurs Res 2009;18(2):172-93.
·
Jatoi A, Windschitl HE, Loprinzi CL, Sloan
JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE,
Novotny PJ, Christensen B. Dronabinol versus megestrol acetate versus
combination therapy for cancer-associated anorexia: a North Central Cancer
Treatment Group study. Journal of Clinical Oncology 2002;20(2):567-573.
·
Regelson W, Butler JR, Schulz J, Kirk T, Peek
L, Green ML, Zalis MO. Delta-9-tetrahydrocannabinol as an effective
antidepressant and appetite-stimulating agent in advanced cancer patients.
In: Braude MC, Szara S, editors. Pharmacology of marihuana. Vol 2. New York:
Raven Press, 1976. p. 763-776.
·
Wadleigh R, Spaulding GM, Lumbersky B, Zimmer
M, Shepard K, Plasse T. Dronabinol enhancement of appetite in cancer patients.
Proc Am Soc Oncology 1990; 9: 331.
o
Strasser F, Luftner D, Possinger K, Ernst G,
Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T. Comparison of
orally administered cannabis extract and delta-9-tetrahydrocannabinol in
treating patients with cancer-related anorexia-cachexia syndrome: a
multicenter, phase III, randomized, double-blind, placebo-controlled clinical
trial from the Cannabis-in-Cachexia-Study-Group. J Clin Oncol
2006;24(21):3394-400.
o
Brisbois TD,
de Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M, Macdonald N,
Baracos VE, Wismer WV. Delta-9-tetrahydrocannabinol
may palliate altered chemosensory perception in cancer patients: results of a
randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011 Feb 22. [in druk]
o
Strasser F, Luftner D, Possinger K, Ernst G,
Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T. Comparison of
orally administered cannabis extract and delta-9-tetrahydrocannabinol in
treating patients with cancer-related anorexia-cachexia syndrome: a
multicenter, phase III, randomized, double-blind, placebo-controlled clinical
trial from the Cannabis-in-Cachexia-Study-Group. J Clin Oncol
2006;24(21):3394-400.
·
Plasse TF, Gorter RW, Krasnow SH, Lane M,
Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol.
Pharmacology, Biochemistry and Behavior 1991;40:695-700.
·
Nelson K, Walsh D, Deeter P, Sheehan F. A
phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in
cancer-associated anorexia. Journal of Palliative Care 1994;10:14-18.
·
Gottschling S. Cannabinoide bei Kindern. Angewandte Schmerztherapie und
Palliativmedizin 2011;(1):55-57.
·
Volicer L, Stelly M, Morris J, McLaughlin J,
Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in
patients with Alzheimer's disease. International Journal of Geriatric
Psychiatry 1997;12:913-919.
·
Patel S, Shua-Haim JR, Pass M. Safety and
efficacy of dronabinol in the treatment of agitation in patients with
Alzheimer’s disease with anorexia: A retrospective chart review. Abstract, 11th
International Conference of the IPA, 17-22 August 2003, Chicago.
·
Wilson MM, Philpot C, Morley JE. Anorexia of
aging in long term care: is dronabinol an effective appetite stimulant? - a
pilot study. J Nutr Health Aging 2007;11(2):195-8.
o
Gross H, Ebert MH, Faden VB, Goldberg SC,
Kaye WH, Caine ED, Hawks R, Zinberg N. A double-blind trial of delta
9-tetrahydrocannabinol in primary anorexia nervosa. Journal of Clinical Psychopharmacology
1983;3(3):165-171.
·
Bergmann K-C. [Dronabinol, a possible new
therapeutic option in patients with COPD and pulmonal cachexia] [Article in
German]. Abstract, 2005 Conference of the German Society for Pneumology, 17
March 2005, Berlin.
·
Foltin RW, Fishman MW, Brady JV. Behavioral
analysis of marijuana effects on food intake in humans. Pharmacology, Biochemistry
and Behavior 1986;25:577-582.
·
Foltin RW, Fischman MW, Byrne MF. Effects of
smoked marijuana on food intake and body weight of humans living in a
residential laboratory. Appetite 1988;11(1):1-14.
o
Killestein J, Hoogervorst EL, Reif M, Kalkers
NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH. Safety,
tolerability, and efficacy of orally administered cannabinoids in MS. Neurology
2002;58(9):1404-7.
·
Petro DJ, Ellenberger C. Treatment of human
spasticity with D9-tetrahydrocannabinol.
Journal of Clinical Pharmacology 1981;(Suppl 21):413S-416S.
·
Ungerleider JT, Andyrsiak T, Fairbanks L,
Ellison GW, Myers LW. D9-THC in the
treatment of spasticity associated with multiple sclerosis. Advances in Alcohol
and Substance Abuse 1987;7:39-50.
·
Zajicek J, Fox P, Sanders H, Wright D,
Vickery J, Nunn A, Thompson A, on behalf of the UK MS Research Group.
Cannabinoids for treatment of spasticity and other symptoms related to multiple
sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet
2003; 362(9385): 1517-1526.
·
Zajicek JP, Sanders HP, Wright DE, Vickery
PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ. Cannabinoids
in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months
follow up. J Neurol Neurosurg Psychiatry 2005;76(12):1664-9.
·
Martyn CN, Illis LS, Thom J. Nabilone in the
treatment of multiple sclerosis. Lancet 1995;345:579.
·
Vaney C, Heinzel-Gutenbrunner M, Jobin P,
Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M. Efficacy of
tetrahydrocannabinol in patients refractory to standard antiemetic
therapy.Efficacy, safety and tolerability of an orally administered cannabis
extract in the treatment of spasticity in patients with multiple sclerosis: a
randomized, double-blind, placebo-controlled, crossover study. Multiple
Sclerosis 2004;10(4):417-24.
·
Wade DT, Makela P, Robson P, House H, Bateman
C. Do cannabis-based medicinal extracts have general or specific effects on
symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled
study on 160 patients. Multiple Sclerosis 2004;10(4):434-41.
·
Zajicek J, Fox P, Sanders H, Wright D,
Vickery J, Nunn A, Thompson A, on behalf of the UK MS Research Group.
Cannabinoids for treatment of spasticity and other symptoms related to multiple
sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet
2003; 362(9385): 1517-1526.
·
Zajicek JP, Sanders HP, Wright DE, Vickery
PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ. Cannabinoids
in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months
follow up. J Neurol Neurosurg Psychiatry 2005;76(12):1664-9.
·
Wade DT, Makela PM, House H, Bateman C,
Robson P. Long-term use of a cannabis-based medicine in the treatment of
spasticity and other symptoms in multiple sclerosis. Mult Scler
2006;12(5):639-45.
·
Collin C, Ambler Z, Kent R, McCalla R. A
randomised controlled study of Sativex® in patients with symptoms of spasticity
due to multiple sclerosis. 22nd Congress of the ECTRIMS, 27-30 September 2006,
Madrid, Spain.
·
Collin C, Davies P, Mutiboko IK, Ratcliffe S,
for the Sativex Spasticity in MS Study Group. Randomized controlled trial of
cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J
Neurology 2007;14(3):290–296.
·
Conte A,
Bettolo CM, Onesti E, Frasca V, Iacovelli E, Gilio F, Giacomelli E, Gabriele M,
Aragona M, Tomassini V, Pantano P, Pozzilli C, Inghilleri M. Cannabinoid-induced
effects on the nociceptive system: a neurophysiological study in patients with
secondary progressive multiple sclerosis. Eur J Pain 2009;13(5):472-7.
o Centonze D, Mori F, Koch G, Buttari F, Codecà C, Rossi S, Cencioni MT,
Bari M, Fiore S, Bernardi G, Battistini L, Maccarrone M. Lack of effect of
cannabis-based treatment on clinical and laboratory measures in multiple
sclerosis. Neurol Sci 2009;30(6):531-4.
·
Novotna
A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C,
Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A,
Montalban X, Klimek A, Davies P; the Sativex Spasticity Study Group. A
randomized, double-blind, placebo-controlled, parallel-group, enriched-design
study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with
refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18(9):1122-1131.
·
Meinck HM, Schönle PWA, Conrad B. Effect of
cannabinoids on spasticity and ataxia in multiple sclerosis. Journal of
Neurology 1989;236:120-122.
v Greenberg
HS, Werness SAS, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects
of smoking marijuana on balance in patients with multiple sclerosis and normal
volunteers. Clinical Pharmacology and Therapeutics 1994;55:324-328.
·
Deutsch SI, Rosse RB, Connor JM, Burket JA,
Murphy ME, Fox FJ. Current status of cannabis treatment of multiple sclerosis
with an illustrative case presentation of a patient with MS, complex vocal
tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol.
CNS Spectr 2008;13(5):393-403.
·
Consroe P, Musty R, Rein J, Tillery W,
Pertwee R. The perceived effects of smoked cannabis on patients with multiple
sclerosis. European Neurology 1997;38:44-48.
·
Page SA, Verhoef MJ, Stebbins RA, Metz LM,
Levy JC. Cannabis use as described by people with multiple sclerosis. Can J
Neurol Sci 2003;30(3):201-5.
·
Chong MS, Wolff K, Wise K, Tanton C, Winstock
A, Silber E. Cannabis use in patients with multiple sclerosis. Mult Scler
2006;12(5):646-51.
·
Hodges C. Personal account of medical use of
cannabis. J Cannabis Ther 2002;2(3-4):155-60.
·
Hanigan WC, Destree R, Truong XT. The effect
of D9-THC on human
spasticity. Clinical Pharmacology and Therapeutics 1986;39:198.
·
Maurer M, Henn V, Dittrich A, Hofmann A.
Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a
single case double-blind trial. European Archives of Psychiatry and Clinical
Neuroscience 1990;240:1-4.
·
Hagenbach U, Luz S, Ghafoor N, Berger JM,
Grotenhermen F, Brenneisen R, Mäder M. The treatment of spasticity with
Delta9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2007;45(8):551-62.
·
Pooyania S, Ethans K, Szturm T, Casey A,
Perry D. A randomized, double-blinded, crossover pilot study assessing the
effect of nabilone on spasticity in persons with spinal cord injury. Arch Phys
Med Rehabil 2010;91(5):703-7.
·
Kogel RW, Johnson PB, Chintam R, Robinson CJ,
Nemchausky BA. Treatment of spasticity in spinal cord injury with dronabinol, a
tetrahydrocannabinol derivative. American Journal of Therapeutics 1995;2(10):799-805.
·
Malec J, Harvey RF, Cayner JJ. Cannabis
effect on spasticity in spinal cord injury. Archives of Physical Medicine and
Rehabilitation 1982;63:116-118.
·
Consroe P, Tillery W, Rein J, Musty RE.
Reported Marijuana effects in patients with spinal cord injury. 1998 Symposium
on the Cannabinoids. Burlington: International Cannabinoid Research Society,
1998, p. 64.
·
Dunn M, Davis R. The perceived effects of
marijuana on spinal cord injured males. Paraplegia 1974;12:175.
·
Wade DT, Robson P, House H, Makela P, Aram J.
A preliminary controlled study to determine whether whole-plant cannabis
extracts can improve intractable neurogenic symptoms. Clinical Rehabilition 2003;17:18-26.
·
Brenneisen R, Egli A, Elsohly MA, Henn V,
Spiess Y. The effect of orally and rectally administered
delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients.
International Journal of Clinical Pharmacology and Therapeutics
1996;34:446-452.
·
Lorenz R. A casuistic rationale for the
treatment of spastic and myocloni in a childhood neurodegenerative disease:
neuronal ceroid lipofuscinosis of the type Jansky-Bielschowsky. Neuro
Endocrinol Lett 2002;23(5-6):387-90.
·
Gottschling S. [Cannabinoides en niños]
[Artículo en alemán] Cannabinoide bei Kindern. Angewandte Schmerztherapie und
Palliativmedizin 2011;(1):55-57.
·
Petro DJ. Marihuana as a therapeutic agent
for muscle spasm or spasticity. Psychosomatics 1980;21:81-85.
·
Randall RC, ed. Muscle Spasm, Pain &
Marijuana Therapy. Washington, DC: Galen Press, 1991.
·
Schweizer A,
Bircher HP. Reposition of a dislocated shoulder under use of cannabis.
Wilderness Environ Med 2009;20(3):301-2.
·
Brenneisen R, Egli A, Elsohly MA, Henn V,
Spiess Y. The effect of orally and rectally administered
delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients.
International Journal of Clinical Pharmacology and Therapeutics
1996;34:446-452.
·
Maurer M, Henn V, Dittrich A, Hofmann A.
Delta-9-THC shows antispastic and analgesic effects in a single case double
blind trial. European Archives of Psychiatry and Clinical Neuroscience
1990;240:1-4.
·
Berman JS, Symonds C, Birch R. Efficacy of
two cannabis based medicinal extracts for relief of central neuropathic pain
from brachial plexus avulsion: results of a randomised controlled trial. Pain
2004;112(3):299-306.
·
Svendsen KB, Jensen TS, Bach FW. Does the
cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised
double blind placebo controlled crossover trial. BMJ 2004;329(7460):253.
o
Rintala DH, Fiess RN, Tan G, Holmes SA, Bruel
BM. Effect of dronabinol on central neuropathic pain after spinal cord injury:
a pilot study. Am J Phys Med Rehabil 2010;89(10):840-8.
·
Wissel J, Haydn T, Müller J, Brenneis C, Berger
T, Poewe W, Schelosky LD. Low dose treatment with the synthetic cannabinoid
Nabilone significantly reduces
spasticity-related pain : a double-blind placebo-controlled cross-over
trial. J Neurol 2006;253(10):1337-41.
o
Frank B, Serpell MG, Hughes J, Matthews JN,
Kapur D. Comparison of analgesic effects and patient tolerability of nabilone
and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double
blind study. BMJ 2008;336(7637):199-201.
·
Wade DT, Robson P, House H, Makela P, Aram J.
A preliminary controlled study to determine whether whole-plant cannabis
extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation
2003;17:18-26.
·
Berman J, Lee J, Cooper M, Cannon A, Sach J,
McKerral S, Taggart M, Symonds C, Fishel K, Birch R. Efficacy of two
cannabis-based medicinal extracts for relief of central neuropathic pain from
brachial plexus avulsion: results of a randomised controlled trial.
Anaesthesia, 2003;58:938.
·
Rog DJ, Nurmikko TJ, Friede T, Young CA.
Randomized, controlled trial of cannabis-based medicine in central pain in
multiple sclerosis. Neurology 2005;65(6):812-9.
o
Ernst G, Denke C, Reif M, Schnelle M,
Hagmeister H. Standardized cannabis extract in the treatment of postherpetic
neuralgia: a randomized, double-blind, placebo-controlled cross-over study.
IACM 3rd Conference on Cannabinoids in Medicine, 9-10 September 2005, Leiden,
International Association for Cannabis as Medicine.
·
Rog DJ, Nurmikko TJ, Young CA. Oromucosal
delta-9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with
multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin
Ther 2007;29(9):2068-79.
·
Nurmikko TJ, Serpell MG, Hoggart B, Toomey
PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain
characterised by allodynia: a randomised, double-blind, placebo-controlled
clinical trial. Pain 2007;133(1-3):210-20.
·
Selvarajah
D, Gandhi R, Emery CJ, Tesfaye S. Randomised Placebo Controlled Double Blind
Clinical Trial of Cannabis Based Medicinal Product (Sativex) in Painful
Diabetic Neuropathy: Depression is a Major Confounding Factor. Diabetes Care
2010;33(1):128-30.
·
Abrams DI, Jay CA, Shade SB, Vizoso H, Reda
H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful
HIV-associated sensory neuropathy: A randomized placebo-controlled trial.
Neurology 2007;68(7):515-21.
·
Wilsey B, Marcotte T, Tsodikov A, Millman J,
Bentley H, Gouaux B, Fishman S. A randomized, placebo-controlled, crossover
trial of cannabis cigarettes in neuropathic pain. J Pain 2008;9(6):506-21.
·
Ellis RJ,
Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H,
Atkinson JH. Smoked medicinal
cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial.
Neuropsychopharmacology 2009;34(3):672-680.
o
Lindstrom P, Lindblom U, Boreus L. Lack of
effect of cannabidiol in sustained neuropathia. Paper presented at '87
International Conference on Cannabis, Melbourne, September 2-4, 1987. Cited
from: Consroe P, Sandyk R. Potential role of cannabinoids for therapy of
neurological disorders. In: Murphy L, Bartke A, eds. Marijuana/Cannabinoids.
Neurobiology and Neurophysiology. Boca Raton, CRC Press, 1992:459-524.
·
Karst M, Salim K, Burstein S, Conrad I, Hoy
L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic
neuropathic pain: a randomized controlled trial. JAMA 2003;290(13):1757-62.
o
Clermont-Gnamien S, Atlani S, Attal N, Le Mercier
F, Guirimand F, Brasseur L. [The therapeutic use of D9-tetrahydrocannabinol
(dronabinol) in refractory neuropathic pain] [Article in French] Presse Med
2002;31(39 Pt 1):1840-5.
·
Finnegan-Ling D, Musty RE. Marinol and
phantom limb pain; a case study. In: 1994 Symposium on the Cannabinoids.
Burlington, Vermont: International Cannabinoid Research Society, p. 53.
o
Attal N, Brasseur L, Guirimand D,
Clermond-Gnamien S, Atlami S, Bouhassira D. Are oral cannabinoids safe and
effective in refractory neuropathic pain? Eur J Pain 2004;8:173–177.
·
Rog DJ, Nurmikko TJ, Young CA. Oromucosal
delta-9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with
multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin
Ther 2007;29(9):2068-79.
·
Toth C,
Au S. A prospective identification of neuropathic pain in specific chronic
polyneuropathy syndromes and response to pharmacological therapy. Pain
2008;138(3):657-66.
·
Bestard
JA, Toth CC. An Open-Label Comparison of Nabilone and Gabapentin as Adjuvant
Therapy or Monotherapy in the Management of Neuropathic Pain in Patients with
Peripheral Neuropathy. Pain Pract
2011;11(4):353-68.
·
Dunn M, Davis R. The perceived effects of
marijuana on spinal cord injured males. Paraplegia 1974;12:175.
·
Consroe P, Musty R, Rein J, Tillery W,
Pertwee R. The perceived effects of smoked cannabis on patients with multiple
sclerosis. European Neurology 1997;38:44-48.
·
Petro DJ. Marihuana as a therapeutic agent
for muscle spasm or spasticity. Psychosomatics 1980;21:81-85.
·
Page SA, Verhoef MJ, Stebbins RA, Metz LM,
Levy JC. Cannabis use as described by people with multiple sclerosis. Can J
Neurol Sci 2003;30(3):201-5.
·
Prentiss D, Power R, Balmas G, Tzuang G,
Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed
in a public health care setting. J Acquir Immune Defic Syndr 2004;35(1):38-45.
·
Woolridge E, Barton S, Samuel J, Osorio J,
Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical
symptoms. J Pain Symptom Manage 2005;29(4):358-67.
·
Chong MS, Wolff K, Wise K, Tanton C, Winstock
A, Silber E. Cannabis use in patients with multiple sclerosis. Mult Scler
2006;12(5):646-51.
·
Noyes R, Brunk SF, Baram DA, Canter A.
Analgesic effects of delta-9-THC. Journal of Clinical Pharmacology
1975;15:139-143.
·
Noyes R, Brunk ST, Avery DH, Canter A. The
analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical
Pharmacology and Therapeutics 1975;18:84-89.
o
Johnson JR, Burnell-Nugent M, Lossignol D,
Ganae-Motan ED, Potts R, Fallon MT. Multicenter, Double-Blind, Randomized,
Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and
Tolerability of THC:CBD Extract and THC Extract in Patients With Intractable
Cancer-Related Pain. J Pain Symptom Manage 2010;39(2):167-79.
·
Johnson JR, Burnell-Nugent M, Lossignol D,
Ganae-Motan ED, Potts R, Fallon MT. Multicenter, Double-Blind, Randomized,
Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and
Tolerability of THC:CBD Extract and THC Extract in Patients With Intractable
Cancer-Related Pain. J Pain Symptom Manage 2010;39(2):167-79.
·
Jochimsen PR, Lawton RL, VerSteeg K, Noyes Jr
R. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical
Pharmacology and Therapeutics 1978;24:223-7
·
Staquet M, Gantt C, Machin D. Effect of a
nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology
and Therapeutics 1978;23:397-401
·
Butler JR
Peek LA Regelson W Moore MM
Lubin LA. Treatment effects of delta-9-THC in an advanced cancer
population. In: Cohen S, Stillman RC, eds. The therapeutic potential of
marihuana. Plenum Medical Book, New York 1976.
·
Maida V, Ennis M, Irani S, Corbo M, Dolzhykov
M. Adjunctive nabilone in cancer pain and symptom management: a prospective
observational study using propensity scoring. J Support Oncol 2008;6(3):119-24.
·
Blake DR, Robson P, Ho M, Jubb RW, McCabe CS.
Preliminary assessment of the efficacy, tolerability and safety of a
cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid
arthritis. Rheumatology (Oxford) 2006;45(1):50-2.
·
Skrabek RQ, Galimova L, Ethans K, Perry D.
Nabilone for the treatment of pain in fibromyalgia. J Pain 2008;9(2):164-73.
·
Ware MA,
Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in
fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010;110(2):604-10.
·
Schley M, Legler A, Skopp G, Schmelz M,
Konrad C, Rukwied R. Delta-9-THC based monotherapy in fibromyalgia patients on
experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res
Opin 2006;22(7):1269-1276.
·
Fiz J,
Durán M, Capellà D, Carbonell J, Farré M. Cannabis use in patients with
fibromyalgia: effect on symptoms relief and health-related quality of life.
PLoS One 2011;6(4):e18440.
Fiz J, Duran M, Langohr K, Capellà D, Farré M. Symptoms relief and
improved mental health in fibromyalgia patients using cannabis. Results of an
observational study. IACM 4th Conference on Cannabinoids in Medicine, 5-6
October 2007, Cologne, International Association for Cannabis as Medicine.
·
Narang S, Gibson D, Wasan AD, Ross EL, Michna
E, Nedeljkovic SS, Jamison RN. Efficacy of dronabinol as an adjuvant treatment
for chronic pain patients on opioid therapy. J Pain 2008;9(3):254-64.
·
Holdcroft A, Smith M, Jacklin A, Hodgson H,
Smith B, Newton M, Evans F. Pain relief with oral cannabinoids in familial
Mediterranean fever. Anaesthesia 1997;52:483-488.
·
Notcutt W, Price M, Miller R, Newport S,
Phillips C, Simmons S, Sansom C. Initial experiences with medicinal extracts of
cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia
2004;59(5):440-52.
·
Ware MA, Ducruet T, Robinson AR. Evaluation
of herbal cannabis characteristics by medical users: a randomized trial. Harm
Reduct J 2006;3(1):32
·
Pinsger M, Schimetta W, Volc D, Hiermann E,
Riederer F, Polz W. [Benefits of an add-on treatment with the synthetic
cannabinomimetic nabilone on patients with chronic pain - a randomized
controlled trial.] [Artikel in deutsch] Wien Klin Wochenschr
2006;118(11-12):327-35.
·
Phan NQ,
Siepmann D, Gralow I, Ständer S. Adjuvant topical therapy with a cannabinoid
receptor agonist in facial postherpetic neuralgia. J Dtsch Dermatol Ges 2010;8(2):88-91.
·
Haroutiunian S, Rosen G, Shouval R, Davidson
E. Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant
pain. J Pain Palliat Care Pharmacother 2008;22(3):213-7.
·
Elsner F, Radbruch L, Sabatowski R.
[Tetrahydrocannabinol for treatment of chronic pain] [Article in German]. Pain
2001;15(3):200-4.
·
Noyes R, Baram DA. Cannabis analgesia.
Comprehensive Psychiatry 1974:15:531-535.
·
Ware MA, Doyle CR, Woods R, Lynch ME, Clark
AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey.
Pain 2003;102(1-2):211-216.
·
Lynch ME, Clark AJ. Cannabis reduces opioid
dose in the treatment of chronic non-cancer pain. J Pain Symptom Manage 2003;25(6):496-8.
·
Howard J, Anie KA, Holdcroft A, Korn S,
Davies SC. Cannabis use in sickle cell disease: a questionnaire study. Br J
Haematol 2005;131(1):123-8.
·
Russo EB, Mathre ML, Byrne A, Velin R, Bach
PJ, Sanchez-Ramos J, et al. Chronic cannabis use in the Compassionate
Investigational New Drug Program: An examination of benefits and adverse
effects of legal clinical cannabis. J Cannabis Ther 2002;2(1):3-57.
·
Aggarwal
SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Characteristics
of patients with chronic pain accessing treatment with medical cannabis in
Washington State. J Opioid Manag 2009;5(5):257-86.
o
Raft D, Gregg J, Ghia J, Harris L. Effects of
intravenous tetrahydrocannabinol on experimental and surgical pain:
psychological correlates of the analgesic response. Clinical Pharmacology and
Therapeutics 1977;21:26-33.
o
Buggy DJ, Toogood L, Maric S, Sharpe P,
Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol
in postoperative pain. Pain 2003;106(1-2):169-72.
o
Seeling W, Kneer L, Buchele B, Gschwend JE,
Maier L, Nett C, Simmet T, Steffen P, Schneider M, Rockemann M.
[(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not
act synergistically in postoperative pain.] [Article in German]. Anaesthesist
2006;55(4):391-400.
·
Holdcroft A, Maze M, Dore C, Tebbs S,
Thompson S. A multicenter dose-escalation study of the analgesic and adverse
effects of an oral cannabis extract (Cannador) for postoperative pain
management. Anesthesiology 2006;104(5):1040-1046.
o
Beaulieu P. Effects of nabilone, a synthetic
cannabinoid, on postoperative pain. Can J Anaesth 2006;53(8):769-75.
·
Jain AK, Ryan JR, McMahon FG, Smith G.
Evaluation of intramuscular levonantradol and placebo in acute postoperative
pain. Journal of Clinical Pharmacology 1981;21(suppl 8-9):S320-S326
·
Kantor TG, Hopper M. A study of
levonantradol, a cannabinol derivative, for analgesia in post operative pain.
Pain 1981; (suppl): S37.
o
Ostenfeld T, Price J, Albanese M, Bullman J,
Guillard F, Meyer I, Leeson R, Costantin C, Ziviani L, Nocini PF, Milleri S. A
randomized, controlled study to investigate the analgesic efficacy of single
doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in
patients with acute pain following third molar tooth extraction. Clin J Pain
2011;27(8):668-76.
o
Naef M, Curatolo M, Petersen-Felix S,
Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral
delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in
healthy subjects under experimental pain conditions. Pain 2003;105(1-2):79-88.
·
Roberts JD, Gennings C, Shih M. Synergistic
affective analgesic interaction between delta-9-tetrahydrocannabinol and
morphine. Eur J Pharmacol 2006;530(1-2):54-8.
o
Redmond WJ, Goffaux P, Potvin S, Marchand
S. Analgesic and antihyperalgesic
effects of nabilone on experimental heat pain.
Curr Med Res Opin 2008;24(4):1017-24.
·
Greenwald MK, Stitzer ML Antinociceptive,
subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol
Depend 2000;59(3):261-75.
·
Wallace M, Schulteis G, Atkinson JH,
Wolfson T, Lazzaretto D, Bentley H, Gouaux B, Abramson I. Dose-dependent
effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in
healthy volunteers. Anesthesiology 2007;107(5):785-796.
o
Kraft B, Frickey NA, Kaufmann RM, Reif M,
Frey R, Gustorff B, Kress HG. Lack of
analgesia by oral standardized cannabis extract on acute inflammatory pain and
hyperalgesia in volunteers. Anesthesiology 2008;109(1):101-10.
·
Raby WN, Modica PA, Wolintz RJ, Murtaugh K.
Dronabinol reduces signs and symptoms of idiopathic intracranial hypertension:
a case report. J Ocul Pharmacol Ther 2006;22(1):68-75.
·
Robbins MS, Tarshish S, Solomon S, Grosberg BM. Cluster Attacks
Responsive to Recreational Cannabis and Dronabinol. Headache 2009;49(6):914-6.
·
Raby WN, Modica PA, Wolintz RJ, Murtaugh K.
Dronabinol reduces signs and symptoms of idiopathic intracranial hypertension:
a case report. J Ocul Pharmacol Ther 2006;22(1):68-75.
·
Robbins MS, Tarshish S, Solomon S, Grosberg BM. Cluster Attacks
Responsive to Recreational Cannabis and Dronabinol. Headache 2009;49(6):914-6.
·
Russo EB. Hemp for headache: An in-depth
historical and scientific review of cannabis in migraine treatment. J Cannabis
Ther 2001;1(2):21-92.
o
Weber M,
Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic
lateral sclerosis: a randomised, double-blind crossover trial. J Neurol
Neurosurg Psychiatry 2010;81(10):1135-40.
·
Amtmann D, Weydt P, Johnson KL, Jensen MP,
Carter GT. Survey of cannabis use in patients with amyotrophic lateral
sclerosis. Am J Hosp Palliat Care 2004;21(2):95-104.
·
Carter GT, Rosen BS. Marijuana in the
management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care
2001;18(4):264-70.
·
Hagenbach U, Ghafoor N, Brenneisen R, Luz S,
Mäder M. Clinical investigation of D-9-tetrahydrocannabinol
(THC) as an alternative therapy for overactive bladders in spinal cord injury
(SCI) patients? Abstract, 2001 Congress on Cannabis and the Cannabinoids,
International Association for Cannabis as Medicine, 25-27 October 2001,
Cologne, Germany.
·
Freeman
RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect
of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled
trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006;17(6):636-41.
·
Brady CM, DasGupta R, Dalton C, Wiseman OJ,
Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for
bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis
2004;10(4):425-33.
·
de Ridder D, Constantinescu CS,Fowler C,
Kavia R, Sarantis N. Randomised controlled study of cannabis-based medicine
(Sativex®) in patients suffering from multiple sclerosis associated detrusor
overactivity. 22nd Congress of the ECTRIMS, 27-30 September 2006, Madrid,
Spain.
·
Freeman
RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect
of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled
trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006;17(6):636-41.
·
Kavia RB, De Ridder D, Constantinescu CS,
Stott CG, Fowler CJ. Randomized controlled trial of Sativex to treat detrusor
overactivity in multiple sclerosis. Mult Scler 2010;16(11):1349-59.
·
Beaumont
H, Jensen J, Carlsson A, Ruth M, Lehmann A, Boeckxstaens GE. Effect of
Delta(9)-tetrahydrocannabinol, a cannabinoid receptor agonist, on the
triggering of transient lower oesophageal sphincter relaxations in dogs and
humans. Br J Pharmacol 2009;156(1):153-62.
·
Esfandyari T, Camilleri M, Busciglio I,
Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist
on colonic motor and sensory functions
in humans: a randomized, placebo-controlled study. Am J Physiol
Gastrointest Liver Physiol 2007;293(1):G137-45.
o
Klooker TK, Leliefeld KE, Van Den Wijngaard
RM, Boeckxstaens GE. The
cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect
visceral sensitivity to rectal distension in healthy volunteers and IBS
patients. Neurogastroenterol Motil 2011;23(1):30-5, e2.
·
Wong BS,
Camilleri M, Busciglio I, Carlson P, Szarka LA, Burton D, Zinsmeister AR. Pharmacogenetic
Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility in
Patients with Non-Constipated Irritable Bowel Syndrome. Gastroenterology, 28.
Juli 2011 [im Druck]
·
Lal S, Prasad
N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H. Cannabis use amongst
patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol
2011;23(10):891-6.
·
Naftali T,
Lev LB, Yablekovitz D, Half E, Konikoff FM. Treatment of Crohn's disease with
cannabis: an observational study. Isr Med Assoc J 2011;13(8):455-8.
·
Lal S,
Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H. Cannabis use
amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol
2011;23(10):891-6.
·
·
Russo E. Cannabis treatments in obstetrics
and gynecology: A historical review. J Cannabis Ther 2002;2(3-4):5-35.
·
Clifford DB. Tetrahydrocannabinol for tremor
in multiple sclerosis. Annals of Neurology 1983;13:669-671.
o
Fox P, Bain PG, Glickman S, Carroll C,
Zajicek J. The effect of cannabis on tremor in patients with multiple
sclerosis. Neurology 2004;62(7):1105-9.
o
Fox SH, Kellett M, Moore AP, Crossman AR,
Brotchie JM. Randomised, double-blind, placebo-controlled trial to assess the
potential of cannabinoid receptor stimulation in the treatment of dystonia.
Movement Disorders 2002;17(1):145-149.
·
Snider SR, Consroe P. Treatment of Meige's
syndrome with cannabidiol. Neurology 1984;34(Suppl):147.
·
Sandyk R, Snider SR, Consroe P, Elias SM.
Cannabidiol in dystonic movement disorders. Psychiatry Research 1986;18:291.
·
Consroe P, Sandyk R, Snider SR. Open label
evaluation of cannabidiol in dystonic movement disorders. International Journal
of Neuroscience 1986;30:277-282.
·
Sieradzan KA, Fox SH, Dick J, Brotchie JM.
The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced
dyskinesia in patients with idiopathic Parkinson's disease (PD). Movement
Disorders 1998;13(Suppl 2):29.
·
Beckmann
Y, Seçil Y, Güngör B, Yiğit T. Tardive Dystonia and the Use of Cannabis.
Turk Psikiyatri Derg 2010;21(1):90-91.
·
Beckmann
Y, Seçil Y, Güngör B, Yiğit T. Tardive Dystonia and the Use of Cannabis.
Turk Psikiyatri Derg 2010;21(1):90-91.
·
Gilson I, Busalacchi M. Marijuana for
intractable hiccups. Lancet 1998; 351(9098): 267.
·
Müller-Vahl KR, Schneider U, Koblenz A,
Jobges M, Kolbe H, Daldrup T, Emrich HM. Treatment of Tourette's syndrome with
Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial.
Pharmacopsychiatry 2002;35(2):57-61.
·
Müller-Vahl KR, Schneider U, Prevedel H,
Theloe K, Kolbe H, Daldrup T, Emrich HM. Delta 9-tetrahydrocannabinol (THC) is
effective in the treatment of tics in Tourette syndrome: a 6-week randomized
trial. Journal of Clinical Psychiatry. 2003;64(4):459-65.
·
Müller-Vahl KR, Schneider U, Kolbe H, Emrich
HM. Treatment of Tourette-Syndrome with delta-9-Tetrahydrocannabinol. American
Journal of Psychiatry 1999;156:495.
·
Deutsch SI, Rosse RB, Connor JM, Burket JA,
Murphy ME, Fox FJ. Current status of cannabis treatment of multiple sclerosis
with an illustrative case presentation of a patient with MS, complex vocal tics,
paroxysmal dystonia, and marijuana dependence treated with dronabinol. CNS
Spectr 2008;13(5):393-403.
·
Müller-Vahl KR, Schneider U, Emrich HM.
Combined treatment of Tourette syndrome with delta-9-THC and dopamine receptor
agonists. J Cannabis Ther 2002;2(3-4):145-54.
·
Hasan A,
Rothenberger A, Münchau A, Wobrock T, Falkai P, Roessner V. Oral
delta9-tetrahydrocannabinol improved refractory gilles de la tourette syndrome
in an adolescent by increasing intracortical inhibition: a case report. J Clin
Psychopharmacol 2010;30(2):190-2.
·
Brunnauer A, Segmiller FM, Volkamer T,
Laux G, Müller N, Dehning S. Cannabinoids improve driving ability in a
Tourette's patient. Psychiatry
Res, 9. Juni 2011
·
Müller-Vahl KR, Kolbe H, Schneider U, Emrich
HM. Cannabinoids: Possible role in pathophysiology of Gilles de la
Tourette-syndrome. Acta Psychiatrica Scandinavica 1998;97:1-5.
·
Sandyk R, Awerbuch G. Marijuana and
Tourette's Syndrome. Journal of Clinical Psychopharmacology 1988;8:444-445.
·
Hemming M, Yellowlees PM. Effective treatment
of Tourette's syndrome with marijuana. J Psychopharmacol 1993; 7: 389-91.
·
Farooq MU, Ducommun E, Goudreau J. Treatment
of a hyperkinetic movement disorder during pregnancy with dronabinol.
Parkinsonism Relat Disord 2009;15(3):249-51.
·
Aharonovich E, Garawi F, Bisaga A, Brooks D,
Raby WN, Rubin E, Nunes EV, Levin FR. Concurrent cannabis use during treatment
for comorbid ADHD and cocaine dependence: effects on outcome. Am J Drug Alcohol
Abuse. 2006;32(4):629-35.
·
Strohbeck-Kuehner P, Skopp G, Mattern R.
[Fitness to drive in spite (because) of THC] [Article in German]. Arch Kriminol
2007;220(1-2):11-9.
·
Strohbeck-Kuehner P, Skopp G, Mattern R.
[Fitness to drive in spite (because) of THC] [Article in German]. Arch Kriminol
2007;220(1-2):11-9.
·
O'Connell TJ, Bou-Matar CB. Long term
marijuana users seeking medical cannabis in California (2001-2007):
demographics, social characteristics, patterns of cannabis and other drug use
of 4117 applicants. Harm Reduct J
2007;4:16.
·
Schindler F, Anghelescu I, Regen F,
Jockers-Scherubl M. Improvement in refractory obsessive compulsive disorder
with dronabinol. Am J Psychiatry 2008;165(4):536-7.
·
Grant JE, Odlaug BL, Chamberlain SR, Kim SW.
Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a
pilot study. Psychopharmacology (Berl), 19. Mai 2011
o
Carroll CB, Bain PG, Teare L, Liu X, Joint C,
Wroath C, Parkin SG, Fox P, Wright D,
Hobart J, Zajicek JP. Cannabis for dyskinesia in Parkinson disease: a
randomized double-blind crossover study. Neurology 2004;63(7):1245-50.
o Frankel JP,
Hughes A, Lees AJ, Stern GM. Marijuana for Parkinsonian tremor. Journal of
Neurology, Neurosurgery and Psychiatry 1990;53:436.
o
Consroe P, Laguna J, Allender J, Snider S,
Stern L, Sandyk R, Kennedy K, Schram K. Controlled clincal trial of cannabidiol
in Huntington's disease. Pharmacology, Biochemistry and Behavior.
1991;40(3):701-8.
v Müller-Vahl
KR, Schneider U, Emrich HM. Nabilone deteriorates choreatic movements in
Huntington`s disease. Movement Disorders 1999b;14:1038-40.
o
Maas AI, Murray G, Henney H 3rd, Kassem N,
Legrand V, Mangelus M, Muizelaar JP, Stocchetti N, Knoller N; Pharmos TBI
investigators. Efficacy and safety of dexanabinol in severe traumatic brain
injury: results of a phase III randomised, placebo-controlled, clinical trial.
Lancet Neurol 2006;5(1):38-45.
·
Raby WN, Modica PA, Wolintz RJ, Murtaugh K.
Dronabinol reduces signs and symptoms of idiopathic intracranial hypertension:
a case report. J Ocul Pharmacol Ther 2006;22(1):68-75.
·
Ständer S, Reinhardt HW, Luger TA. [Topical
cannabinoid agonists: An effective new possibility for treating chronic
pruritus.] [Article in German]. Hautarzt 2006;57(9):801-7.
·
Neff GW, O'Brien CB, Reddy KR, Bergasa NV,
Regev A, Molina E, Amaro R, Rodriguez
MJ, Chase V, Jeffers L, Schiff E. Preliminary observation with
dronabinol in patients with intractable pruritus secondary to cholestatic liver
disease. Am J Gastroenterol 2002;97(8):2117-9.
·
Maida V. Nabilone for the treatment of
paraneoplastic night sweats: a report of four cases. J Palliat Med
2008;11(6):929-34.
·
Cunha JM, Carlini EA, Pereira AE, Ramos OL,
Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R. Chronic
administration of cannabidiol to healthy volunteers and epileptic patients.
Pharmacology 1980;21(3):175-85.
·
Consroe PF, Wood GC, Buchsbaum H.
Anticonvulsant nature of marihuana smoking. JAMA 1975;234(3):306-7.
o
Ames FR, Cridland S.: Anticonvulsant effect
of cannabidiol [letter]. South African Medical Journal 1986;69:14.
o
Trembly B, Sherman M. Double-blind clinical
study of cannabidiol as a secondary anticonvulsant. Conference on Cannabis and
Cannabinoids, Kolympari/Crete, July 1990, cited according to: Consroe P, Sandyk
R. Potential role of cannabinoids for therapy of neurological disorders. In:
Murphy L, Bartke A, eds. Marijuana/Cannabinoids, Neurobiology and
Neurophysiology. Boca Raton: CRC Press 1992, 459-524. [Commentary: No
effect of Cannabidiol (300 mg/day) in 10 patients.]
·
Trembly B, Sherman M. Double-blind clinical
study of cannabidiol as a secondary anticonvulsant. Conference on Cannabis and
Cannabinoids, Kolympari/Crete, July 1990, cited according to: Consroe P, Sandyk
R. Potential role of cannabinoids for therapy of neurological disorders. In:
Murphy L, Bartke A, eds. Marijuana/Cannabinoids, Neurobiology and
Neurophysiology. Boca Raton: CRC Press 1992, 459-524. [Commentary:
Reduction in Reduzierung in frequency of seizures with cannabidiol (900-1200
mg/day) in one patient.]
·
Corral VL. Differential effects of medical
marijuana based on strain and route of administration: A three-year
observational study. J Cannabis Ther 2001;1(3-4):43-59.
·
Mortati K, Dworetzky B, Devinsky O.
Marijuana: an effective antiepileptic treatment in partial epilepsy? A case
report and review of the literature. Rev Neurol Dis 2007;4(2):103-6.
·
Meyniel C, Ollivier Y, Hamidou M, Péréon
Y, Derkinderen P. Dramatic improvement of refractory Isaacs' syndrome after treatment
with dronabinol. Clin Neurol Neurosurg 2011;113(4):323-4.
·
Crawford WJ, Merritt JC. Effects of
tetrahydrocannabinol on arterial and intraocular hypertension. International Journal
of Clinical Pharmacololgy and Biopharmacy 1979;17(5):191-196.
·
Merritt JC, Crawford WJ, Alexander PC, Anduze
AL, Gelbart SS. Effect of marihuana on intraocular and blood pressure in
glaucoma. Ophthalmology 1980;87(3):222-8.
·
Tomida I, Azuara-Blanco A, House H, Flint M,
Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on
intraocular pressure: a pilot study. J Glaucoma 2006;15(5):349-353.
o
Tomida I, Azuara-Blanco A, House H, Flint M,
Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on
intraocular pressure: a pilot study. J Glaucoma 2006;15(5):349-353.
·
Hepler RS, Frank IM, Petrus R. Ocular effects
of marijuana smoking. In: Braude MC, Szara S, eds. The pharmacology of
marihuana. Raven Press: New York: 1976;815-828.
·
Russo EB, Mathre ML, Byrne A, Velin R, Bach
PJ, Sanchez-Ramos J, et al. Chronic cannabis use in the Compassionate
Investigational New Drug Program: An examination of benefits and adverse
effects of legal clinical cannabis. J Cannabis Ther 2002;2(1):3-57.
o
Merritt JC, Perry DD, Russell DN, Jones BF.
Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma. Journal
of Clinical Pharmacololgy 1981;21(8-9 Suppl):467S-471S.
·
Cooler P, Gregg JM. Effect of
delta-9-tetrahydrocannabinol on intraocular pressure in humans. Southern
Medical Journal 1977;70(8):951-954.
·
Jones RT, Benowitz N, Herning RI. The
clinical relevance of cannabis tolerance and dependence. Journal of Clinical
Pharmacology 1981;21:143S-152S.
o
Levitt M, Wilson A, Bowman D, Kemel S,
Krepart G, Marks V, Schipper H, Thomson G, Weinerman B, Weinerman R.
Physiologic observations in a controlled clinical trial of the antiemetic
effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer
chemotherapy. Ophthalmologic implications. J Clin Pharmacol 1981;21(8-9
Suppl):103S-109S.
·
Perez-Reyes M, Wagner D, Wall ME. Davis KH.
Intravenous administration of cannabinoids and intraocular pressure. In: Braude
MC, Szara S, ed. Pharmacology of marihuana. New York: Raven Press,
1976;829-832.
·
Plange N, Arend KO, Kaup M, Doehmen B, Adams
H, Hendricks S, Cordes A, Huth J, Sponsel WE, Remky A. Dronabinol and retinal
hemodynamics in humans. Am J Ophthalmol 2007;143(1):173-4.
·
Hepler RS, Frank IM. Marihuana smoking and
intraocular pressure. Journal of the American Medical Association
1971;217:1392.
·
Flom MC, Adams AJ, Jones RT. Marijuana
smoking and reduced intraocular pressure in human eye: Drug action or
epiphenomenon? Investigative Ophthalmology 1975;14:52-55.
·
Hepler R S, Frank I M, Petrus R. Ocular
effects of marijuana smoking. In: Braude MC, Szara S, eds. The pharmacology of
marihuana. New York: Raven Press, 1976;815-828.
·
Russo EB, Merzouki A, Molero Mesa J, Frey KA,
Bach PJ. Cannabis improves night vision: A pilot study of dark adaptometry and
scotopic sensitivity in kif smokers of the Rif Mountains of Northern Morocco. J
Ethnopharmacol 2004;93(1):99-104.
·
Russo EB, Merzouki A, Molero Mesa J, Frey KA,
Bach PJ. Cannabis improves night vision: A pilot study of dark adaptometry and
scotopic sensitivity in kif smokers of the Rif Mountains of Northern Morocco. J
Ethnopharmacol 2004;93(1):99-104.
·
Tashkin DP, Reiss S, Shapiro BJ, Calvarese B,
Olsen JL, Lodge JW. Bronchial effects of aerosolized delta
9-tetrahydrocannabinol in healthy and asthmatic subjects. American Review of
Respiratory Disease 1977;115(1):57-65.
·
Williams SJ, Hartley JP, Graham JD.
Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of
asthmatic patients. Thorax 1976;31(6):720-723.
·
Tashkin DP, Shapiro BJ, Lee YE, Harper CE.
Effects of smoked marijuana in experimentally induced asthma. American Review
of Respiratory Disease 1975;112(3):377-386.
·
Vachon L, Mikus P, Morrissey W, FitzGerald M,
Gaensler E. Bronchial effect of marihuana smoke in asthma. In: Braude MC, Szara
S, eds. The pharmacology of marihuana. Raven Press: New York: 1976;777-784.
o
Gong H Jr, Tashkin DP, Calvarese B.
Comparison of bronchial effects of nabilone and terbutaline in healthy and
asthmatic subjects. Journal of Clinical Pharmacology 1983;23(4):127-133
·
Tashkin DP, Shapiro BJ, Frank IM. Acute
effects of smoked marijuana and oral delta9-tetrahydrocannabinol on specific
airway conductance in asthmatic subjects. American Review for Respiratory
Diseases. 1974 Apr;109(4):420-8.
·
Tashkin DP, Shapiro BJ, Frank IM. Acute
effects of smoked marijuana and oral delta9-tetrahydrocannabinol on specific
airway conductance in asthmatic subjects. American Review for Respiratory
Diseases 1974 Apr;109(4):420-8.
·
Gong H Jr, Tashkin DP, Simmons MS, Calvarese
B, Shapiro BJ. Acute and subacute bronchial effects of oral cannabinoids.
Clinical Pharmacology and Therapeutics 1984;35(1):26-32.
·
Tashkin DP, Reiss S, Shapiro BJ, Calvarese B,
Olsen JL, Lodge JW. Bronchial effects of aerosolized delta
9-tetrahydrocannabinol in healthy and asthmatic subjects. American Review of
Respiratory Disease 1977;115(1):57-65.
·
Gong H Jr, Tashkin DP, Calvarese B.
Comparison of bronchial effects of nabilone and terbutaline in healthy and
asthmatic subjects. Journal of Clinical Pharmacology 1983;23(4):127-133.
·
Pickering
EE, Semple SJ, Nazir MS, Murphy K, Snow TM, Cummin AR, Moosavi S, Guz A,
Holdcroft A. Cannabinoid effects on ventilation and breathlessness: A pilot
study of efficacy and safety. Chron Respir Dis 2011;8(2):109-18.
·
Vandrey
R, Umbricht A, Strain EC. Increased Blood Pressure Following Abrupt Cessation
of Daily Cannabis Use. J Addict Med 2011;5(1):16-20.
·
Guzmán M, Duarte MJ, Blázquez C, Ravina J,
Rosa MC, Galve-Roperh I, Sánchez C, Velasco G, González-Feria L. A pilot
clinical study of Delta9-tetrahydrocannabinol in patients with recurrent
glioblastoma multiforme. Br J Cancer 2006;95(2):197-203.
·
Liang C,
McClean MD, Marsit C, Christensen B, Peters E, Nelson HH, Kelsey KT. A
population-based case-control study of marijuana use and head and neck squamous
cell carcinoma. Cancer Prev Res (Phila Pa) 2009;2(8):759-68.
·
Foroughi
M, Hendson G, Sargent MA, Steinbok P. Spontaneous regression of septum
pellucidum/forniceal pilocytic astrocytomas-possible role of Cannabis
inhalation. Childs Nerv Syst 2011;27(4):671-9.
·
Volicer L, Stelly M, Morris J, McLaughlin J,
Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in
patients with Alzheimer's disease. International Journal of Geriatric
Psychiatry 1997;12:913-919.
·
Patel S, Shua-Haim JR, Pass M. Safety and
efficacy of dronabinol in the treatment of agitation in patients with
Alzheimer’s disease with anorexia: A retrospective chart review. Abstract, 11th
International Conference of the IPA, 17-22 August 2003, Chicago.
·
Ross JS, Shua-Haim JR. Open-label study of
dronabinol in the treatment of refractory agitation in Alzheimer’s disease: a
pilot study. Abstract, ASCP's 34th Annual Meeting, 12-15 November 2003, San
Antonio, USA.
·
Walther S, Mahlberg R, Eichmann U, Kunz D.
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.
Psychopharmacology (Berl) 2006;185(4):524-8.
·
Passmore
MJ. The cannabinoid receptor agonist nabilone for the treatment of
dementia-related agitation. Int J Geriatr Psychiatry 2008;23(1):116-7.
·
Jacobus
J, McQueeny T, Bava S, Schweinsburg BC, Frank LR, Yang TT, Tapert SF. White
matter integrity in adolescents with histories of marijuana use and binge drinking.
Neurotoxicol Teratol 2009;31(6):349-55.
·
Leweke FM, Koethe D, Gerth CW, Nolden BM,
Schreiber D, Hänsel A, Neatby MA, Juelicher A, Hellmich M, Klosterkötter J.
Cannabidiol as an antipsychotic. A double-blind, controlled clinical trial on
cannabidiol vs. amisulpride in acute schizophrenia. IACM 3rd Conference on
Cannabinoids in Medicine, 9-10 September 2005, Leiden, International
Association for Cannabis as Medicine.
o
Zuardi AW, Hallak JE, Dursun SM, Morais SL,
Faria Sanches R, Musty RE, Crippa JA. Cannabidiol monotherapy for
treatment-resistant schizophrenia. J Psychopharmacol 2006;20(5):683-6.
·
Zuardi AW, Morais SL, Guimarães FS, Mechoulam
R. Antipsychotic effect of cannabidiol. Journal of Clinical Psychiatry
1995;56:485-486.
·
Schwarcz
G, Karajgi B, McCarthy R. Synthetic delta-9-tetrahydrocannabinol (dronabinol)
can improve the symptoms of schizophrenia. J Clin Psychopharmacol
2009;29(3):255-8.
·
Schwarcz
G, Karajgi B. Improvement in refractory psychosis with dronabinol: four case
reports. J Clin Psychiatry. 2010;71(11):1552-3.
·
Schwarcz
G, Karajgi B, McCarthy R. Synthetic delta-9-tetrahydrocannabinol (dronabinol)
can improve the symptoms of schizophrenia. J Clin Psychopharmacol
2009;29(3):255-8.
·
Schwarcz
G, Karajgi B. Improvement in refractory psychosis with dronabinol: four case
reports. J Clin Psychiatry. 2010;71(11):1552-3.
·
Grinspoon L, Bakalar JB. The use of cannabis
as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for
clinical research. Journal of Psychoactive Drugs 1998;30(2):171-7.
o
El-Mallakh RS, Brown C. The effect of extreme
marijuana use on the long-term course of bipolar I illness: a single case
study. J Psychoactive Drugs 2007;39(2):201-2.
·
Ringen PA, Vaskinn A, Sundet K, Engh JA,
Jónsdóttir H, Simonsen C, Friis S, Opjordsmoen S, Melle I, Andreassen OA.
Opposite relationships between cannabis use and neurocognitive functioning in
bipolar disorder and schizophrenia. Psychol Med 2010;40(8):1337-47.
·
Regelson W, Butler JR, Schulz J, Kirk T, Peek
L, Green ML, Zalis MO. Delta-9-tetrahydrocannabinol as an effective
antidepressant and appetite-stimulating agent in advanced cancer patients.
In: Braude MC, Szara S, editors. Pharmacology of marihuana. Vol 2. New York:
Raven Press, 1976. p. 763-776.
·
Ware MA, Adams H, Guy GW. The medicinal use
of cannabis in the UK: results of a nationwide survey. Int J Clin Pract
2005;59(3):291-5.
·
Bergamaschi
MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F,
Quevedo J, Roesler R, Schröder N, Nardi AE, Martín-Santos R, Hallak JE, Zuardi
AW, Crippa JA. Cannabidiol Reduces the Anxiety Induced by Simulated Public
Speaking in Treatment-Naïve Social Phobia Patients. Neuropsychopharmacology.
2011 Feb 9. [in druk]
·
Crippa JA,
Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Simões MV,
Bhattacharyya S, Fusar-Poli P, Atakan Z, Santos Filho A, Freitas-Ferrari MC,
McGuire PK, Zuardi AW, Busatto GF, Hallak JE. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized
social anxiety disorder: a preliminary report. J Psychopharmacol
2011;25(1):121-30.
·
Villagonzalo
KA, Dodd S, Ng F, Mihaly S, Langbein A, Berk M. The relationship between
substance use and posttraumatic stress disorder in a methadone maintenance
treatment program. Compr Psychiatry
2011;52(5):562-6.
·
Cornelius
JR, Kirisci L, Reynolds M, Clark DB, Hayes J, Tarter R. PTSD contributes to
teen and young adult cannabis use disorders. Addict Behav 2010;35(2):91-4.
·
Reznik I. Medical cannabis use in
post-traumatic stress disorder: a naturalistic observational study. Abstract
presented at the Cannabinoid Conference 2011, 8-10 September, Bonn, Germany.
·
Mikuriya TH. Cannabis substitution. An
adjunctive therapeutic tool in the treatment of alcoholism. Medical Times
1970;98(4):187-91.
·
Mikuriya TH. Cannabis as a substitute for
alcohol: a harm-reduction approach. J Cannabis Ther 2004;4(1):79-93.
·
Reiman A.
Cannabis as a substitute for alcohol and other drugs Harm Reduct J 2009;6:35.
o
Hermann D, Klages E, Welzel H, Mann K,
Croissant B. Low efficacy of non-opioid drugs in opioid withdrawal symptoms.
Addict Biol 2005;10(2):165-9.
·
O'Connell TJ, Bou-Matar CB. Long term
marijuana users seeking medical cannabis in California (2001-2007):
demographics, social characteristics, patterns of cannabis and other drug use
of 4117 applicants. Harm Reduct J 2007;4:16.
·
Raby WN, Carpenter KM, Rothenberg J, Brooks
AC, Jiang H, Sullivan M, Bisaga A, Comer S, Nunes EV Intermittent marijuana use
is associated with improved retention in naltrexone treatment for opiate-dependence.
Am J Addict 2009;18(4):301-8.
·
Aharonovich E, Garawi F, Bisaga A, Brooks D,
Raby WN, Rubin E, Nunes EV, Levin FR. Concurrent cannabis use during treatment
for comorbid ADHD and cocaine dependence: effects on outcome. Am J Drug Alcohol
Abuse. 2006;32(4):629-35.
·
Labigalini E Jr, Rodrigues LR, Da Silveira
DX. Therapeutic use of cannabis by crack addicts in Brazil. J Psychoactive
Drugs 1999;31(4):451-5.
·
Dreher M. Crack heads and roots daughters:
The therapeutic use of cannabis in Jamaica. J Cannabis Ther 2002;2(3-4):121-33.
·
Haney M, Hart CL, Vosburg SK, Nasser J,
Bennett A, Zubaran C, Foltin RW. Marijuana withdrawal in humans: effects of
oral THC or divalproex. Neuropsychopharmacology 2004;29(1):158-70.
·
Levin FR, Kleber HD. Use of dronabinol for cannabis dependence: two case
reports and review. Am J Addict 2008;17(2):161-4.
·
Nicholson AN, Turner C, Stone BM, Robson PJ.
Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and
early-morning behavior in young adults. J Clin Psychopharmacol
2004;24(3):305-13.
·
Grinspoon L, Bakalar JB. Marihuana, the
forbidden medicine. Rev. and exp. ed. New Haven: Yale University Press; 1997.
·
Randall RC, O'Leary AM. Marijuana Rx: The
patients' fight for medicinal pot. New York: Thunder's Mouth Press; 1998.
·
Corral VL. Differential effects of medical
marijuana based on strain and route of administration: A three-year
observational study. J Cannabis Ther 2001;1(3-4):43-59.
·
Grotenhermen F, Schnelle M. Survey on the
medical use of cannabis and THC in Germany. J Cannabis Ther 2003;3(2):17-40.
·
Gieringer D. Medical use of cannabis:
Experience in California. In: Grotenhermen F, Russo E, editors. Cannabis and
cannabinoids: Pharmacology, toxicology, and therapeutic potential. Binghamton,
NY: Haworth Press; 2001. p. 153-70.
·
Ware MA, Adams H, Guy GW. The medicinal use
of cannabis in the UK: results of a nationwide survey. Int J Clin Pract
2005;59(3):291-5.
·
Russo EB, Mathre ML, Byrne A, Velin R, Bach
PJ, Sanchez-Ramos J, et al. Chronic cannabis use in the Compassionate
Investigational New Drug Program: An examination of benefits and adverse
effects of legal clinical cannabis. J Cannabis Ther 2002;2(1):3-57.
·
O'Connell TJ, Bou-Matar CB. Long term
marijuana users seeking medical cannabis in California (2001-2007):
demographics, social characteristics, patterns of cannabis and other drug use
of 4117 applicants. Harm Reduct J
2007;4:16.
·
Bottorff
JL, Johnson JL, Moffat BM, Mulvogue T. Relief oriented use of marijuana by
teens. Subst Abuse Treat Prev Policy 2009;4(1):7.